Abstract: The present invention relates to an aqueous pharmaceutical composition suitable for long-term storage of polypeptides containing an Fc domain of an immunoglobulin, methods of manufacture, methods of administration and kits containing same.
Type:
Grant
Filed:
December 7, 2009
Date of Patent:
February 21, 2012
Assignee:
Immunex Corporation
Inventors:
Wayne R. Gombotz, Richard L. Remmele, Jr.
Abstract: The present invention provides antibodies and immunologically functional fragments thereof that specifically bind Dkk-1 polypeptides. The subject antibodies and fragments bind with high affinity to a conformational epitope located in the carboxy region of the Dkk-1 protein. Methods for preparing such antibodies or fragments thereof as well as physiologically acceptable compositions containing the antibodies or fragments are also provided. Use of the antibodies and fragments to treat various diseases including bone disorders, inflammatory diseases, neurological diseases, ocular diseases, renal diseases, pulmonary diseases and skin diseases are also disclosed.
Type:
Grant
Filed:
October 21, 2009
Date of Patent:
January 24, 2012
Assignee:
Amgen Inc.
Inventors:
Ji Li, Wenyan Shen, Hsieng Sen Lu, William Gleason Richards
Abstract: This invention is in the general field of recombinant expression of polypeptides in animal cell culture. More particularly, the invention concerns improved selection in cells of recombinantly engineered vectors designed to express polypeptides.
Abstract: The present invention provides for improved compositions comprising a PEGsTNF-R1 which, in addition to having useful higher concentrations, demonstrate decreased viscosity (<400 cP) and improved stability.
Abstract: This invention relates to the general field of recombinant expression of polypeptides in animal cell culture. More particularly, the invention concerns improved selection in cells of recombinantly engineered vectors designed to express polypeptides.
Abstract: Novel MK61 polypeptides and nucleic acid molecules encoding the same. The invention also provides vectors, host cells, selective binding agents, and methods for producing MK61 polypeptides. Also provided for are methods for the treatment, diagnosis, amelioration, or prevention of diseases with MK61 polypeptides.
Type:
Grant
Filed:
May 17, 2006
Date of Patent:
August 4, 2009
Assignee:
Amgen Inc.
Inventors:
Lars Eyde Theill, Richard Yeh, Scott Michael Silbiger, Gang Yu, Giorgio Senaldi
Abstract: The invention relates to the use of a phosphate glass as a phosphorous source in the media of high cell density bacterial fermentation processes in order to reduce metallophosphate precipitation reactions. The methods of the invention demonstrate a practical method for controlling levels of metallophosphate precipitation in both the nutrient media and the fermentor which also result in increased cell densities and are useful in a variety of high cell density bacterial fermentation processes.
Type:
Grant
Filed:
October 4, 2006
Date of Patent:
June 3, 2008
Assignee:
Amgen Inc.
Inventors:
Craig Eric Curless, Jeffrey Burke Baclaski
Abstract: The invention relates to the use of a phosphate glass as a phosphorus source in the media of high cell density bacterial fermentation processes in order to reduce metallophosphate precipitation reactions. The methods of the invention demonstrate a practical method for controlling levels of metallophosphate precipitation in both the nutrient media and the fermentor which also result in increased cell densities and are useful in a variety of high cell density bacterial fermentation processes.
Type:
Grant
Filed:
August 21, 1996
Date of Patent:
October 10, 2006
Assignee:
Amgen Inc.
Inventors:
Craig Eric Curless, Jeffrey Burke Baclaski
Abstract: This invention concerns interactions among APRIL/G70, AGP-3/BLYS, BCMA, and TACI and related methods of use and compositions of matter. It has been found that (1) sAPRIL/G70 binds to the cell-surface receptors BCMA and TACI on T and B lymphoma cells, resulting in stimulation of proliferation of primary human and mouse B and T cells both in vitro and in vivo; (2) APRIL competes with AGP3's binding to TACI and BCMA; (3) sBCMA inhibits APRIL and AGP3 binding to its receptors; (4) sBCMA ameliorates T cell dependent and T cell independent humoral immune responses in vivo; (5) sTACI inhibits APRIL and AGP3 binding to its receptors and ameliorates T cell dependent and T cell independent humoral immune responses in vivo; and (6) BCMA exhibits similarity with TACI within a single cysteine rich domain located N-terminal to a potential transmembrane domain. These discoveries provides a strategy for development of therapeutics for treatment of autoimmune diseases, and cancer, for prevention of transplant rejection.
Abstract: The present invention broadly relates to chemical modification of biologically active proteins or analogs thereof. More specifically, the present invention describes novel methods for site-specific chemical modification of various proteins, and resultant compositions having improved biocompatibility and bioactivity.
Abstract: Disclosed are methods for improving the solubility of a protein of interest produced recombinantly by expressing the protein of interest as a fusion protein with Uracil DNA glycosylase inhibitor (UGI).
Abstract: LERK-5 polypeptides are disclosed, along with DNA sequences, vectors and transformed host cells useful in producing LERK-5. The LERK-5 polypeptides bind to elk and to hek, which are members of the eph/elk family of receptor tyrosine kinases.
Abstract: The invention is directed to purified and isolated novel DAKAR (death associated kinase containing ankyrin repeat) polypeptides, the nucleic acids encoding such polypeptides, processes for production of recombinant forms of such polypeptides, antibodies generated against these polypeptides, fragmented peptides derived from these polypeptides and the uses of the above.